Cardio-Optics Inc.
This article was originally published in Start Up
Executive Summary
Blood is not only thicker than water, it is a great deal more opaque, a property that makes it difficult for interventional cardiologists to navigate accurately in and around the heart to repair defects and place devices. Now Cardio-optics Inc. hopes to give surgeons a tool that helps them see directly forward through blood in real-time, to help them accurately perform a large variety of therapeutic and diagnostic procedures in blood-filled environs.
You may also be interested in...
Tapping the Potential of Atrial Fibrillation Devices
A solid foundation has been laid in the field of devices for atrial fibrillation; clinical trials have underscored the efficacy of cardiac ablation devices compared to drugs, reimbursement is in place for both surgical and catheter-based ablation procedures, and large companies have invested heavily in the technologies, validating the entire field. Early devices on the market are bringing in some revenues for their developers, but much remains to be done before atrial fibrillation becomes the multi-billion market everyone talks about. The biggest challenge that lies ahead: clinical trials, for today, all ablation devices are used off-label for atrial fibrillation.
Tapping the Potential of Atrial Fibrillation Devices
A solid foundation has been laid in the field of devices for atrial fibrillation; clinical trials have underscored the efficacy of cardiac ablation devices compared to drugs, reimbursement is in place for both surgical and catheter-based ablation procedures, and large companies have invested heavily in the technologies, validating the entire field. Early devices on the market are bringing in some revenues for their developers, but much remains to be done before atrial fibrillation becomes the multi-billion market everyone talks about. The biggest challenge that lies ahead: clinical trials, for today, all ablation devices are used off-label for atrial fibrillation.
Tinkering with the Ticker
Established heart valve companies are putting out second and third generation devices, while start-ups are developing novel technologies to overcome the drawbacks associated with mechanical and tissue valves. The replacement valve market is essentially flat; future growth will come from macro factors such as an aging population or improving economies in third world countries, but companies continue to improve products to retain or capture market share from each other. Meanwhile, start-ups see a new market opening up for percutaneous technologies. Such technologies promise to offer a solution for patients who aren't candidates for surgery. Early intervention could also delay the need for valve replacement procedures. While new heart valves aren't readily adopted by conservative surgeons that already have a host of options that are proven to be safe, interventional cardiologists are eager for the new procedures that the percutaneous technologies promise.